I was digging deeper into the history of this company and came across a few good article:
1. Feb 22, 2011 - Adam Feuerstien
Delcath drop 28% to $8.00 ...FDA issue "refuse to file" letter.... FDA requested information involving manufacturing plant inspection timing, product & sterilization valitation, and additional safety information.
Note: more information about Phase III was not requested
2. Oct 10, 2012 - Mark Messier - On 8-15-2012 Decalth requested priority review
3. Oct 15, 2012 - Scott Donnelly - FDA accept Delcath application -- Delcath recieve a standard review apploval ...revenue could be as high as $2 Billion.......Phase 2 trial for patients with unresectable liver cancer ---- data show 70% of 20 patients showed a hepatic response after 3 treatments, whereas normalized response rate for these patients under current treatment arm would be 5%.
I am still researching this company. Given the potential for $2B revenue and great phase II result, why is DCTH still trading at $1.5. At this point in time it should be around $10.
$2B is a long ways off, initially, they will be in a 500 million market once FDA approval is given. Revenues in a 500 million market, once insurers reimburse, can put DCTH at a market cap double what it is now. It's going to take years. This stock could easily go to $10, and back down to $2.00 afterwards. GL
I just viewed the slide presentation in the sec fillings on company website. It's a comprehensive slide presentation, and the market is 2.3 billion world wide. This stock is going nowhere but up. June 15th 2013 is the date in the slide presentation that the company has indicated for a PDUFA approval vote. What an opportunity here!